Tandem Diabetes director gets new RSU award

Tandem Diabetes Care director Kathleen McGroddy-Goetz reported compensation-related equity activity.

Rhea-AI Filing Summary

Tandem Diabetes Care director Kathleen McGroddy-Goetz reported compensation-related equity activity. She received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026, which will vest on the one-year anniversary of the grant under the company’s 2023 Long-Term Incentive Plan.

Separately, 8,759 RSUs granted on May 21, 2025 fully vested and converted into common shares. Following these transactions, she directly holds 26,612 shares of common stock. All reported moves are equity awards and RSU vesting, with no open-market buying or selling.

Insider Trade Summary

8,759 shares exercised/converted

Exercise 3 txns

Insider McGroddy-Goetz Kathleen

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	8,759	$0.00	$0.00
Exercise	Common Stock	8,759	$0.00	$0.00
Grant/Award	Restricted Stock Unit	10,220	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 10,220 contracts (Direct); Common Stock — 26,612 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
2. F2. Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.
3. F3. On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.

Key Figures

New RSU grant: 10,220 RSUs Vested RSUs converted: 8,759 RSUs Shares held after transactions: 26,612 shares +1 more

4 metrics

New RSU grant 10,220 RSUs Granted May 20, 2026 under 2023 Long-Term Incentive Plan

Vested RSUs converted 8,759 RSUs Granted May 21, 2025; vested and converted after one year

Shares held after transactions 26,612 shares Common stock directly held following May 2026 transactions

Derivative exercises 8,759 shares Exercise/conversion of RSUs into common stock

Key Terms

Restricted Stock Unit, 2023 Long-Term Incentive Plan, RSU vesting, derivative exercise/conversion

4 terms

Restricted Stock Unit financial

"The director received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2023 Long-Term Incentive Plan financial

"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan"

RSU vesting financial

"Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion for 8,759 Restricted Stock Units into Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TNDM director Kathleen McGroddy-Goetz report?

She reported equity-related acquisitions only. On May 20, 2026 she received 10,220 restricted stock units, and on May 21, 2026 a prior grant of 8,759 RSUs fully vested and converted into common stock, increasing her direct share holdings.

Did the TNDM director buy or sell Tandem Diabetes Care stock on the market?

No open-market trades were reported. All activity involved equity compensation: a new RSU grant and the vesting and conversion of previously granted RSUs into common stock, with no Form 4 codes indicating purchases or sales in the public market.

How many Tandem Diabetes Care shares does the director hold after these Form 4 transactions?

After the reported transactions, Kathleen McGroddy-Goetz directly holds 26,612 shares of Tandem Diabetes Care common stock. This post-transaction balance reflects the conversion of 8,759 vested RSUs into shares and does not include any remaining derivative positions.

What are the terms of the new RSU award reported by TNDM’s director?

The director received 10,220 restricted stock units on May 20, 2026. Each RSU represents a contingent right to one share of common stock or cash, at the company’s discretion, and this grant vests on the one-year anniversary of the grant date under the 2023 Plan.

What happened to the 8,759 RSUs previously granted to the TNDM director?

The 8,759 RSUs granted on May 21, 2025 fully vested and converted into common stock on their one-year anniversary. Upon vesting, all units became Tandem Diabetes Care shares in accordance with the company’s 2023 Long-Term Incentive Plan provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGroddy-Goetz Kathleen

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		M		8,759	A	$0	26,612	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	05/20/2026		A		10,220		(2)	(2)	Common Stock	10,220	$0	10,220	D
Restricted Stock Unit	(1)	05/21/2026		M			8,759	(3)	(3)	Common Stock	8,759	$0	0	D

Explanation of Responses:

1. Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

2. Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

3. On May 21, 2025, the Reporting Person was granted 8,759 RSUs, all of which vested and converted into shares of the Issuers common stock on the one-year anniversary thereof in accordance with the 2023 Plan.

Remarks:

Ex. 24: Power of Attorney

	/s/ Jerilyn Laskie, Attorney-in-Fact for Kathleen McGroddy-Goetz	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)